Advertisement

Radiopharmaceuticals for Therapy of Thyroid Diseases

  • Katia Marzo
Chapter

Abstract

Since the discovery of radium, the medical community has been interested in the application of unsealed radioactive isotopes to target and treat cancer and benign proliferative conditions. Radioactive iodine-131, as non radioactive Iodine, is taken up by thyroid cells, either normal or pathological, therefore thanks to its gamma and beta emissions, represents a radiopharmaceutical of choice for thyroid diseases. We give here a summary of the chemistry, mechanism of uptake and biodistribution of 131-Iodine with regard of its applications in thyroid benign and malignant diseases.The medical community has been interested in the application of unsealed radioactive isotopes to target and treat cancer and benign systemic and locoregional proliferative conditions. Lack of effective system agents coupled with the intention to use targeted therapy for treating cancer made radioisotopes an option for use in cancer.

Keywords

Thyroid Iodine-131 

References

  1. 1.
    Eary JF, Bennet W. Nuclear medicine therapy. Boca Raton, FL: CRC Press; 2007.CrossRefGoogle Scholar
  2. 2.
  3. 3.
    Volterrani D, Erba PA, Mariani G. Fondamenti di Medicina Nucleare. Milano: Springer; 2010.CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Courtesy of G. Pepe. Re-designed from: Ahn BC. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics. 2012;2(4):392–402.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Humanitas Research HospitalRozzanoItaly

Personalised recommendations